Symbols / CYCN $4.10 -33.41% Cyclerion Therapeutics, Inc.
CYCN Chart
About
Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 15.59M |
| Enterprise Value | 23.39M | Income | -3.53M | Sales | 2.07M |
| Book/sh | 2.38 | Cash/sh | 0.75 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -3.13 | PEG | — |
| P/S | 7.52 | P/B | 1.72 | P/C | — |
| EV/EBITDA | — | EV/Sales | 11.28 | Quick Ratio | 4.71 |
| Current Ratio | 5.15 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -1.11 | EPS next Y | -1.31 | EPS Growth | — |
| Revenue Growth | -43.20% | Earnings | 2026-03-31 06:00 | ROA | -31.78% |
| ROE | -39.34% | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | -81.76% | Profit Margin | -170.11% | Shs Outstand | 3.81M |
| Shs Float | 3.49M | Short Float | 2.66% | Short Ratio | 2.06 |
| Short Interest | — | 52W High | 8.48 | 52W Low | 1.03 |
| Beta | — | Avg Volume | 4.73M | Volume | 2.68M |
| Target Price | $8.00 | Recom | None | Prev Close | $6.15 |
| Price | $4.09 | Change | -33.41% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
- CYCN stock is soaring 150% pre-market today — what is fueling the rally? - msn.com Mon, 06 Apr 2026 10
- CYCN Stock Alert: Halper Sadeh LLC is Investigating Whether Cyclerion Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders - Business Wire hu, 02 Apr 2026 05
- If You Invested $1,000 in Cyclerion Therapeutics Inc (CYCN) - Stock Titan Sat, 04 Apr 2026 04
- Why is Cyclerion Therapeutics Stock (CYCN) Up Over 160% Today? - TipRanks Wed, 01 Apr 2026 12
- CYCN Stock Alert: Halper Sadeh LLC is Investigating Whether Cyclerion Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders - The Daily Tribune News hu, 02 Apr 2026 05
- Why is Biotech Stock Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) Gaining? - Investorideas.com Wed, 01 Apr 2026 16
- CYCN Stock Is Soaring 274% Today — What Is Fueling The Rally? - Stocktwits ue, 31 Mar 2026 20
- Cyclerion Therapeutics (CYCN) Stock Surges 160% on Korsana Merger Deal - MEXC Wed, 01 Apr 2026 14
- Cyclerion Therapeutics surges as it agrees to merge with Korsana Biosciences in a deal backed by a large private financing - Quiver Quantitative Wed, 01 Apr 2026 14
- CYCN Earning Date, Earning Analysis and Earning Prediction - Intellectia AI Sat, 04 Apr 2026 16
- Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement - Business Wire Wed, 01 Apr 2026 11
- Korsana Biosciences to go public via Cyclerion (CYCN) reverse merger and $380M PIPE - Stock Titan Wed, 01 Apr 2026 20
- Unusual volume stocks in Thursday's session - ChartMill hu, 02 Apr 2026 17
- Penny Stock CYCN Surged More Than 300% Yesterday. Why, And Should You Chase the Rally Here? - Barchart.com hu, 02 Apr 2026 13
- Cyclerion Therapeutics Stock Soars 350% On Korsana Merger, $380 Million Financing - Benzinga Wed, 01 Apr 2026 14
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
2.07
+3.70%
|
2.00
|
0.00
-100.00%
|
0.30
|
| Operating Revenue |
|
2.07
+3.70%
|
2.00
|
0.00
-100.00%
|
0.30
|
| Operating Expense |
|
7.05
+25.21%
|
5.63
-41.66%
|
9.65
-48.79%
|
18.84
|
| Research And Development |
|
0.96
+235.31%
|
0.29
-81.12%
|
1.51
-74.66%
|
5.98
|
| Selling General And Administration |
|
6.09
+13.96%
|
5.34
-34.31%
|
8.13
-36.76%
|
12.86
|
| General And Administrative Expense |
|
6.09
+13.96%
|
5.34
-34.31%
|
8.13
-36.76%
|
12.86
|
| Other Gand A |
|
6.09
+13.96%
|
5.34
-34.31%
|
8.13
-36.76%
|
12.86
|
| Other Operating Expenses |
|
—
|
—
|
—
|
-1.33
|
| Total Expenses |
|
7.05
+25.21%
|
5.63
-41.66%
|
9.65
-48.79%
|
18.84
|
| Operating Income |
|
-4.97
-37.07%
|
-3.63
+62.39%
|
-9.65
+47.97%
|
-18.54
|
| Total Operating Income As Reported |
|
-4.97
-37.07%
|
-3.63
+71.99%
|
-12.95
+30.15%
|
-18.54
|
| EBITDA |
|
-4.97
-37.07%
|
-3.63
+62.39%
|
-9.65
+47.78%
|
-18.48
|
| Normalized EBITDA |
|
-6.29
-57.60%
|
-3.99
+37.08%
|
-6.34
+65.67%
|
-18.48
|
| Reconciled Depreciation |
|
—
|
—
|
0.00
-100.00%
|
0.07
|
| EBIT |
|
-4.97
-37.07%
|
-3.63
+62.39%
|
-9.65
+47.97%
|
-18.54
|
| Total Unusual Items |
|
1.32
+262.81%
|
0.36
+110.99%
|
-3.30
|
0.00
|
| Total Unusual Items Excluding Goodwill |
|
1.32
+262.81%
|
0.36
+110.99%
|
-3.30
|
0.00
|
| Special Income Charges |
|
1.32
+262.81%
|
0.36
+110.99%
|
-3.30
|
0.00
|
| Other Special Charges |
|
-1.32
-262.81%
|
-0.36
|
—
|
—
|
| Impairment Of Capital Assets |
|
—
|
0.00
-100.00%
|
3.30
|
0.00
|
| Net Income |
|
-3.53
-15.41%
|
-3.06
+41.92%
|
-5.26
+88.06%
|
-44.08
|
| Pretax Income |
|
-3.53
-15.41%
|
-3.06
+75.72%
|
-12.59
+30.98%
|
-18.25
|
| Net Non Operating Interest Income Expense |
|
0.13
-38.46%
|
0.21
-41.90%
|
0.36
+21.77%
|
0.29
|
| Interest Expense Non Operating |
|
—
|
—
|
—
|
—
|
| Net Interest Income |
|
0.13
-38.46%
|
0.21
-41.90%
|
0.36
+21.77%
|
0.29
|
| Interest Expense |
|
—
|
—
|
—
|
—
|
| Interest Income Non Operating |
|
0.13
-38.46%
|
0.21
-41.90%
|
0.36
+21.77%
|
0.29
|
| Interest Income |
|
0.13
-38.46%
|
0.21
-41.90%
|
0.36
+21.77%
|
0.29
|
| Other Income Expense |
|
1.32
+262.81%
|
0.36
+110.99%
|
-3.30
|
—
|
| Other Non Operating Income Expenses |
|
—
|
0.36
|
—
|
—
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-3.53
-15.41%
|
-3.06
+41.92%
|
-5.26
+88.06%
|
-44.08
|
| Net Income From Continuing Operation Net Minority Interest |
|
-3.53
-15.41%
|
-3.06
+75.72%
|
-12.59
+30.98%
|
-18.25
|
| Net Income From Continuing And Discontinued Operation |
|
-3.53
-15.41%
|
-3.06
+41.92%
|
-5.26
+88.06%
|
-44.08
|
| Net Income Continuous Operations |
|
-3.53
-15.41%
|
-3.06
+75.72%
|
-12.59
+30.98%
|
-18.25
|
| Net Income Discontinuous Operations |
|
—
|
0.00
-100.00%
|
7.33
+128.38%
|
-25.83
|
| Normalized Income |
|
-4.84
-41.67%
|
-3.42
+63.18%
|
-9.29
+49.09%
|
-18.25
|
| Net Income Common Stockholders |
|
-3.53
-15.41%
|
-3.06
+41.92%
|
-5.26
+88.06%
|
-44.08
|
| Diluted EPS |
|
—
|
-1.21
+46.22%
|
-2.25
+88.91%
|
-20.28
|
| Basic EPS |
|
—
|
-1.21
+46.22%
|
-2.25
+88.91%
|
-20.28
|
| Basic Average Shares |
|
—
|
2.52
+7.70%
|
2.34
+7.59%
|
2.17
|
| Diluted Average Shares |
|
—
|
2.52
+7.70%
|
2.34
+7.59%
|
2.17
|
| Diluted NI Availto Com Stockholders |
|
-3.53
-15.41%
|
-3.06
+41.92%
|
-5.26
+88.06%
|
-44.08
|
| Total Other Finance Cost |
|
—
|
—
|
—
|
-0.29
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
13.37
|
| Current Assets |
|
8.02
|
| Cash Cash Equivalents And Short Term Investments |
|
7.57
|
| Cash And Cash Equivalents |
|
7.57
|
| Receivables |
|
0.00
|
| Accounts Receivable |
|
0.00
|
| Prepaid Assets |
|
0.44
|
| Other Current Assets |
|
0.01
|
| Total Non Current Assets |
|
5.35
|
| Net PPE |
|
0.00
|
| Gross PPE |
|
0.13
|
| Accumulated Depreciation |
|
-0.13
|
| Properties |
|
—
|
| Machinery Furniture Equipment |
|
0.13
|
| Other Properties |
|
—
|
| Leases |
|
—
|
| Investments And Advances |
|
5.35
|
| Other Investments |
|
5.35
|
| Other Non Current Assets |
|
—
|
| Total Liabilities Net Minority Interest |
|
2.09
|
| Current Liabilities |
|
2.09
|
| Payables And Accrued Expenses |
|
1.97
|
| Payables |
|
1.20
|
| Accounts Payable |
|
1.20
|
| Current Accrued Expenses |
|
0.78
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
0.00
|
| Current Capital Lease Obligation |
|
—
|
| Other Current Liabilities |
|
0.11
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
|
| Long Term Debt And Capital Lease Obligation |
|
—
|
| Long Term Capital Lease Obligation |
|
—
|
| Stockholders Equity |
|
11.29
|
| Common Stock Equity |
|
11.29
|
| Capital Stock |
|
0.00
|
| Common Stock |
|
0.00
|
| Preferred Stock |
|
0.00
|
| Share Issued |
|
2.47
|
| Ordinary Shares Number |
|
2.47
|
| Treasury Shares Number |
|
0.17
|
| Additional Paid In Capital |
|
275.72
|
| Retained Earnings |
|
-264.42
|
| Gains Losses Not Affecting Retained Earnings |
|
-0.01
|
| Other Equity Adjustments |
|
-0.01
|
| Total Equity Gross Minority Interest |
|
11.29
|
| Total Capitalization |
|
11.29
|
| Working Capital |
|
5.94
|
| Invested Capital |
|
11.29
|
| Total Debt |
|
—
|
| Capital Lease Obligations |
|
—
|
| Net Tangible Assets |
|
11.29
|
| Tangible Book Value |
|
11.29
|
| Current Notes Payable |
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-3.31
+23.52%
|
-4.33
+79.60%
|
-21.25
+47.69%
|
-40.61
|
| Cash Flow From Continuing Operating Activities |
|
-3.31
+23.52%
|
-4.33
+79.60%
|
-21.25
+47.69%
|
-40.61
|
| Cash From Discontinued Operating Activities |
|
—
|
—
|
-15.75
|
0.00
|
| Net Income From Continuing Operations |
|
-3.53
-15.41%
|
-3.06
+41.92%
|
-5.26
+88.06%
|
-44.08
|
| Depreciation Amortization Depletion |
|
—
|
—
|
0.00
-100.00%
|
0.07
|
| Depreciation And Amortization |
|
—
|
—
|
0.00
-100.00%
|
0.07
|
| Other Non Cash Items |
|
—
|
-0.36
+97.70%
|
-15.75
|
—
|
| Stock Based Compensation |
|
0.44
-29.44%
|
0.62
-41.42%
|
1.07
-82.93%
|
6.25
|
| Asset Impairment Charge |
|
—
|
0.00
-100.00%
|
3.30
|
0.00
|
| Operating Gains Losses |
|
—
|
—
|
—
|
—
|
| Gain Loss On Sale Of PPE |
|
—
|
—
|
—
|
0.00
|
| Change In Working Capital |
|
-0.23
+85.24%
|
-1.54
+66.57%
|
-4.60
-61.44%
|
-2.85
|
| Change In Receivables |
|
-0.44
+20.14%
|
-0.56
-679.17%
|
0.10
+2300.00%
|
0.00
|
| Changes In Account Receivables |
|
-0.44
+20.14%
|
-0.56
-679.17%
|
0.10
+2300.00%
|
0.00
|
| Change In Prepaid Assets |
|
0.04
+76.19%
|
0.02
-94.21%
|
0.36
+195.12%
|
0.12
|
| Change In Payables And Accrued Expense |
|
0.17
+117.54%
|
-1.00
+81.99%
|
-5.54
-60.24%
|
-3.46
|
| Change In Accrued Expense |
|
0.06
+110.31%
|
-0.55
+85.33%
|
-3.77
+18.07%
|
-4.60
|
| Change In Payable |
|
0.12
+126.52%
|
-0.45
+74.89%
|
-1.77
-255.17%
|
1.14
|
| Change In Account Payable |
|
0.12
+126.52%
|
-0.45
+74.89%
|
-1.77
-255.17%
|
1.14
|
| Change In Other Current Assets |
|
0.01
+200.00%
|
-0.01
-101.04%
|
0.48
+0.00%
|
0.48
|
| Change In Other Current Liabilities |
|
—
|
—
|
—
|
0.00
|
| Investing Cash Flow |
|
—
|
0.00
-100.00%
|
10.40
|
0.00
|
| Cash Flow From Continuing Investing Activities |
|
—
|
—
|
—
|
0.00
|
| Cash From Discontinued Investing Activities |
|
—
|
0.00
-100.00%
|
10.40
|
0.00
|
| Net PPE Purchase And Sale |
|
—
|
—
|
—
|
0.00
|
| Purchase Of PPE |
|
—
|
—
|
—
|
0.00
|
| Sale Of PPE |
|
—
|
—
|
—
|
0.00
|
| Capital Expenditure |
|
—
|
—
|
—
|
—
|
| Financing Cash Flow |
|
3.32
|
0.00
-100.00%
|
5.02
+17224.14%
|
0.03
|
| Cash Flow From Continuing Financing Activities |
|
3.32
|
0.00
-100.00%
|
5.02
+17224.14%
|
0.03
|
| Net Issuance Payments Of Debt |
|
—
|
—
|
—
|
—
|
| Issuance Of Debt |
|
—
|
—
|
—
|
—
|
| Short Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Net Short Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Net Common Stock Issuance |
|
1.25
|
0.00
|
—
|
0.00
|
| Common Stock Payments |
|
-0.13
|
0.00
|
—
|
—
|
| Repurchase Of Capital Stock |
|
-0.13
|
0.00
|
—
|
—
|
| Proceeds From Stock Option Exercised |
|
—
|
0.00
-100.00%
|
5.02
+17224.14%
|
0.03
|
| Net Other Financing Charges |
|
2.08
|
—
|
—
|
—
|
| Changes In Cash |
|
0.01
+100.18%
|
-4.33
+25.54%
|
-5.82
+85.66%
|
-40.58
|
| Effect Of Exchange Rate Changes |
|
0.00
+100.00%
|
-0.01
-175.00%
|
0.01
+166.67%
|
0.00
|
| Beginning Cash Position |
|
3.23
-57.31%
|
7.57
-43.42%
|
13.38
-75.20%
|
53.96
|
| End Cash Position |
|
3.24
+0.25%
|
3.23
-57.31%
|
7.57
-43.42%
|
13.38
|
| Free Cash Flow |
|
-3.31
+23.52%
|
-4.33
+79.60%
|
-21.25
+47.69%
|
-40.61
|
| Common Stock Issuance |
|
1.38
|
0.00
|
—
|
0.00
|
| Issuance Of Capital Stock |
|
1.38
|
0.00
|
—
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-01 View
- 10-K2026-03-30 View
- 8-K2026-02-17 View
- 8-K2026-01-06 View
- 8-K2025-12-01 View
- 10-Q2025-11-12 View
- 8-K2025-09-23 View
- 42025-08-11 View
- 10-Q2025-08-05 View
- 8-K2025-06-18 View
- 8-K2025-05-07 View
- 10-Q2025-05-06 View
- 42025-03-27 View
- 42025-03-27 View
- 8-K2025-03-25 View
- 10-K2025-03-04 View
- 8-K2024-12-17 View
- 42024-11-25 View
- 10-Q2024-11-14 View
- 42024-08-07 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|